The NIH Blueprint for Neurotherapeutics Network (BPN) was launched to enable neuroscientists in academia and biotechnology companies to develop new drugs for nervous system disorders. The BPN provides grant funding as well as free access to CROs (medicinal chemistry, pharmacokinetics/ADME, toxicology, drug manufacturing, drug formulation and phase I clinical trials) and consultants for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. A fundamental hallmark of the program is that the research institution retains the intellectual property rights. The goal is to generate the required data to de-risk further funding for subsequent clinical trials, partnership, or out-licensing. Attendees will hear not just from NIH staff but also grantees who have benefited from the program.